{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(1)"],"submitter":["Loscocco GG"],"pubmed_abstract":["We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 and 2023: median age 59 years (18-95), females 65%, JAK2/CALR/MPL-mutated 66%/19%/4%, triple-negative (TN) 11%. Extreme thrombocytosis (ExT, platelets ≥1000 × 10<sup>9</sup>/L) in 16%, leukocytosis (leukocytes >11 × 10<sup>9</sup>/L) in 16%, and at least one cardiovascular risk factor in 52% of cases. JAK2-mutated patients were older (median 62 years) and CALR-mutated and TN (53 years for both) younger (p < 0.001). Female gender clustered with TN (76%) and JAK2 (67%) vs CALR (46%) mutations (p < 0.001). ExT clustered with CALR (type-2 more than type-1), TN and MPL, and leukocytosis with JAK2 mutation (p < 0.001). In multi"],"journal":["Blood cancer journal"],"pagination":["10"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10796728"],"repository":["biostudies-literature"],"pubmed_title":["One thousand patients with essential thrombocythemia: the Florence-CRIMM experience."],"pmcid":["PMC10796728"],"pubmed_authors":["Loscocco GG","Vannucchi AM","Capecchi G","Guglielmelli P","Atanasio A","Maccari C","Gesullo F","Mannelli F"],"additional_accession":[]},"is_claimable":false,"name":"One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.","description":"We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 and 2023: median age 59 years (18-95), females 65%, JAK2/CALR/MPL-mutated 66%/19%/4%, triple-negative (TN) 11%. Extreme thrombocytosis (ExT, platelets ≥1000 × 10<sup>9</sup>/L) in 16%, leukocytosis (leukocytes >11 × 10<sup>9</sup>/L) in 16%, and at least one cardiovascular risk factor in 52% of cases. JAK2-mutated patients were older (median 62 years) and CALR-mutated and TN (53 years for both) younger (p < 0.001). Female gender clustered with TN (76%) and JAK2 (67%) vs CALR (46%) mutations (p < 0.001). ExT clustered with CALR (type-2 more than type-1), TN and MPL, and leukocytosis with JAK2 mutation (p < 0.001). In multi","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan","modification":"2025-04-04T10:34:33.777Z","creation":"2025-04-04T10:34:33.777Z"},"accession":"S-EPMC10796728","cross_references":{"pubmed":["38238287"],"doi":["10.1038/s41408-023-00968-7"]}}